These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 31549317)

  • 1. The Landmark Series: Non-melanoma Skin Cancers.
    Lee AY; Berman RS
    Ann Surg Oncol; 2020 Jan; 27(1):22-27. PubMed ID: 31549317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances.
    Lessans S; O'Connell KA; Choe J
    Curr Oncol Rep; 2024 Sep; 26(9):1120-1133. PubMed ID: 38954315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updates in the Management of Advanced Nonmelanoma Skin Cancer.
    Yan F; Schmalbach CE
    Surg Oncol Clin N Am; 2024 Oct; 33(4):723-733. PubMed ID: 39244290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers.
    Komatsubara KM; Jeter J; Carvajal RD; Margolin K; Schadendorf D; Hauschild A
    Am Soc Clin Oncol Educ Book; 2017; 37():641-650. PubMed ID: 28561682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapy of skin carcinoma.
    Kempf RA
    Cancer Treat Res; 1995; 78():137-62. PubMed ID: 8595141
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunotherapy for Non-melanoma Skin Cancer.
    Shalhout SZ; Emerick KS; Kaufman HL; Miller DM
    Curr Oncol Rep; 2021 Aug; 23(11):125. PubMed ID: 34448958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Melanoma Skin Cancers: Biological and Clinical Features.
    Cives M; Mannavola F; Lospalluti L; Sergi MC; Cazzato G; Filoni E; Cavallo F; Giudice G; Stucci LS; Porta C; Tucci M
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
    Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
    J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
    Lyseng-Williamson KA; Keating GM
    Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma.
    Villani A; Potestio L; Fabbrocini G; Scalvenzi M
    Adv Ther; 2022 Mar; 39(3):1164-1178. PubMed ID: 35089534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
    Cirrone F; Harris CS
    Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.
    Axelson M; Liu K; Jiang X; He K; Wang J; Zhao H; Kufrin D; Palmby T; Dong Z; Russell AM; Miksinski S; Keegan P; Pazdur R
    Clin Cancer Res; 2013 May; 19(9):2289-93. PubMed ID: 23515405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.
    Peris K; Licitra L; Ascierto PA; Corvò R; Simonacci M; Picciotto F; Gualdi G; Pellacani G; Santoro A
    Future Oncol; 2015; 11(4):703-12. PubMed ID: 25686123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical management of cutaneous malignancies.
    Gibbs P; Gonzalez R; Lee LA; Walsh P
    Clin Dermatol; 2001; 19(3):298-304. PubMed ID: 11479042
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimal treatment of unresectable nonmelanoma skin cancers.
    Olencki T
    J Natl Compr Canc Netw; 2014 May; 12(5 Suppl):789-92. PubMed ID: 24853218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vismodegib: A Review in Advanced Basal Cell Carcinoma.
    Frampton JE; Basset-Séguin N
    Drugs; 2018 Jul; 78(11):1145-1156. PubMed ID: 30030732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma.
    Ascierto PA; Schadendorf D
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36455990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.